首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Mesenchymal Stem Cells for Spinal Cord Injury: Current Options Limitations and Future of Cell Therapy
【2h】

Mesenchymal Stem Cells for Spinal Cord Injury: Current Options Limitations and Future of Cell Therapy

机译:骨髓损伤的间充质干细胞:当前的选择局限性和细胞治疗的未来。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Spinal cord injury (SCI) constitutes an inestimable public health issue. The most crucial phase in the pathophysiological process of SCI concerns the well-known secondary injury, which is the uncontrolled and destructive cascade occurring later with aberrant molecular signaling, inflammation, vascular changes, and secondary cellular dysfunctions. The use of mesenchymal stem cells (MSCs) represents one of the most important and promising tested strategies. Their appeal, among the other sources and types of stem cells, increased because of their ease of isolation/preservation and their properties. Nevertheless, encouraging promise from preclinical studies was followed by weak and conflicting results in clinical trials. In this review, the therapeutic role of MSCs is discussed, together with their properties, application, limitations, and future perspectives.
机译:脊髓损伤(SCI)构成了不可估量的公共健康问题。 SCI病理生理过程中最关键的阶段涉及众所周知的继发性损伤,即随后发生的不受控制的破坏性级联反应,伴随异常的分子信号传导,炎症,血管变化和继发性细胞功能障碍。间充质干细胞(MSCs)的使用代表了最重要和最有希望的测试策略之一。由于它们易于分离/保存及其特性,它们在干细胞的其他来源和类型中的吸引力有所提高。然而,临床前研究令人鼓舞的希望伴随着临床试验中微弱而矛盾的结果。在这篇综述中,讨论了MSC的治疗作用,以及它们的性质,应用,局限性和未来前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号